Iboga microdosing means taking sub-perceptual amounts of iboga root bark or ibogaine — doses too small to produce the visionary experience, significant nausea, or ataxia of a full ceremony. People use it for depression, focus, and mild addiction maintenance. The evidence base is thin, the dosing is not standardised, and the cardiac contraindications that apply at flood-dose levels do not disappear at smaller amounts. That last point is the one most guides understate.
Iboga microdosing involves repeated sub-perceptual doses of iboga root bark or isolated ibogaine — typically 1–5 mg/kg body weight on a spaced schedule — without producing the acute psychoactive or visionary experience of a full flood dose (15–20 mg/kg). It targets mood, cognition, and light addiction maintenance rather than the neurological reset a ceremony produces. No randomised controlled trials exist as of mid-2026. The cardiac risks that apply to ibogaine at any dose remain.
What Iboga Microdosing Is — and What It Is Not
Iboga is the root bark of Tabernanthe iboga, a shrub from the rainforests of Central Africa. In the Bwiti tradition of Gabon, it is used in ceremony — at doses high enough to produce a 12–24 hour initiatory experience. There is no concept of microdosing in traditional Bwiti practice. Microdosing is a Western adaptation, developed outside of that ceremonial context.
A microdose is typically defined as a sub-perceptual amount — small enough that the person can function normally, sleep at normal times, and experience no significant alteration of consciousness. For ibogaine, this generally means 1–5 mg per kilogram of body weight, taken every three to four days. A flood dose — the amount used in full ceremony — is 15–20 mg/kg. The two approaches are separated by an order of magnitude.
People who microdose iboga typically describe improved mood, reduced anxiety, increased focus, and modest reductions in cravings for substances. Some use it as a maintenance protocol after a full ceremony, extending the neuroplasticity window. Others use it as a standalone intervention for mild-to-moderate depression or to reduce alcohol or tobacco use.
What microdosing is not: a substitute for a flood dose in cases of opioid dependence, severe treatment-resistant depression, or PTSD. The neurological reset that a full ceremony produces — the acute interruption of opioid receptor physiology, the disruption of the default mode network, the window of dramatically reduced craving — does not occur at microdose levels. Ibogaine is not a cure for addiction at any dose. At microdose levels, the neurological effects are subtler. That can be appropriate for the right condition. It is not appropriate for conditions that require the more complete intervention.
How a Microdose Differs from a Flood Dose
The difference is not just quantity. It is mechanism and purpose.
A flood dose — 15–20 mg/kg ibogaine — produces an acute experience lasting 12–24 hours. The person cannot function normally. They are lying down, monitored by an on-site medical professional, moving through distinct phases of the experience. The active metabolite noribogaine sustains effects for weeks to months after clearance. The flood dose is used for opioid dependence, severe PTSD, and treatment-resistant depression. The evidence — most notably the 2023 Stanford study published in Nature Medicine, which found 88% reductions in PTSD symptoms and 87% reductions in depression at one month in 30 special operations veterans — applies to flood-dose treatment, not microdosing.
A microdose — 1–5 mg/kg — produces no acute psychoactive experience. The person is functional. There is no 12–24 hour commitment, no multi-day recovery period, no requirement for on-site medical supervision during the dose itself. The effects, when present, are gradual: a slight lifting of mood over days, reduced craving at the margins, improved focus. It is a different kind of intervention suited to different presentations.
People who come to iboga seeking a shortcut to the flood-dose effects through microdosing are going to be disappointed. The medicine does not work on a linear scale where a small amount produces a proportionally smaller version of the same experience. The acute neurological reset — the part that produces the dramatic results in published research — requires the full dose to produce.
What the Research Actually Shows
There are no randomised controlled trials of iboga or ibogaine microdosing as of mid-2026. The evidence base consists of case reports, observational data, and self-reported surveys — all with real methodological limitations.
The most substantial published case evidence is a 2022 case report in BMC Psychiatry documenting sustained improvement in a patient with bipolar depression following an ibogaine microdosing protocol. That is one patient. It is interesting. It is not a basis for clinical conclusions.
In June 2026, researchers published a case series in Frontiers in Pharmacology examining an integrative iboga microdosing protocol in patients with post-concussive and hypoxic brain injury. The findings were encouraging — clinical improvement in a population where few effective options exist. The study was a case series, not a trial, and the population was specific.
The evidence that does exist for ibogaine — the flood-dose Stanford study, the Texas clinical trial programme receiving $50 million in state funding — is for full-dose treatment. People who cite this research as support for microdosing are extrapolating beyond what the data actually supports.
That does not mean microdosing has no value. It means the claim has to match the evidence. At the moment, the evidence supports cautious interest, not clinical confidence.
The Cardiac Risk That Does Not Disappear at Low Doses
This is the part of microdosing guides that receives the least attention and carries the most risk.
Ibogaine — at any dose — blocks hERG potassium channels in the heart. This can prolong the QT interval: the electrical recovery phase of the heartbeat. QT prolongation can trigger Torsades de Pointes, a potentially fatal arrhythmia. The risk is lower at microdose levels than at flood-dose levels, but it does not go to zero. In a person with an undiagnosed Long QT Syndrome, a cardiac arrhythmia, or concurrent use of other QT-prolonging medications, even a microdose carries real cardiovascular risk.
The same is true of drug interactions. The medication contraindications that apply to flood-dose ibogaine — SSRIs, SNRIs, MAOIs, certain antipsychotics, methadone — are not negated by a lower dose. Serotonin syndrome risk from combining ibogaine with SSRIs is dose-dependent but not eliminated at low doses. This is not a theoretical concern. People have had serious cardiovascular events combining ibogaine at low doses with contraindicated medications.
Any provider offering ibogaine microdosing without a baseline EKG and full medication review is not operating safely. Any guide that describes microdosing as "lower risk" without specifying that this is relative — not absolute — is misleading the reader.
Who This Is Not For
Iboga microdosing is not appropriate for everyone, and for some people it is not appropriate at all.
- Anyone with QT prolongation, cardiac arrhythmia, or undiagnosed cardiac conditions. Ibogaine affects cardiac conduction at any dose. A baseline EKG is required before microdosing can be evaluated as a realistic option.
- Anyone currently taking SSRIs or SNRIs. These are absolute contraindications regardless of dose. The risk of serotonin syndrome is real and potentially fatal. A supervised taper, conducted with the prescribing physician, is required before any ibogaine protocol.
- Anyone on methadone. Methadone is itself a QT-prolonging compound. Combined with ibogaine at any dose, the cardiac risk is substantially elevated. A specific supervised transition protocol is required.
- Anyone with severe liver or kidney disease. Both ibogaine and noribogaine are metabolised and cleared through these systems. Impaired function extends exposure unpredictably.
- Anyone in acute psychiatric crisis or with active psychosis. Ibogaine amplifies what is present. Entering any ibogaine protocol — at any dose — in a state of acute destabilisation does not produce stability.
- Anyone seeking to avoid a flood dose that their condition actually requires. If the condition is opioid dependence with significant physical withdrawal history, treatment-resistant depression that has not responded to multiple medications, or complex PTSD with entrenched symptomatology — microdosing is unlikely to be adequate. The people who most want a gentler version of the medicine are often the people who most need the full intervention.
- Pregnancy. Absolute contraindication.
If you are not sure which category applies to you, the honest answer is that this requires a proper screening conversation — not a self-assessment.
Is This Right for You?
ExploreBwiti works with iboga in a ceremonial context, not as a microdosing clinic. We do not offer microdosing protocols. What we observe, from the people who have tried microdosing before coming to full ceremony, is consistent with what the limited research suggests: microdosing can shift the edges — mood, energy, mild craving reduction. It does not produce the structural change that a flood dose can.
The people who arrive at ceremony after months of microdosing tend to arrive more prepared in one respect: they have experienced the medicine in a small way, and they are not naive about what the plant is. They have also arrived because the microdosing was not enough — because the underlying condition requires more than a gradual tune-up.
If you are considering microdosing iboga for mild depression, focus, or as a maintenance protocol after a prior ceremony, a proper medical evaluation is the correct starting point. Not a guide. Not a forum. A physician who knows ibogaine's pharmacology and can review your cardiac history and current medications.
If you are considering whether a full ceremony might be appropriate for your situation, read through our frequently asked questions, review what iboga ceremony involves at ExploreBwiti, and apply if what you read reflects what you need. Every application receives a personal response within 2–3 business days.
If this is not the right path for you — because of cardiac history, current medications, or a condition that requires a different kind of support first — we will tell you directly. That conversation is part of the work. Read more about the integration process and what happens after ceremony before you decide whether this is the right next step.